IMAB - CONSENSUS CO - I-Mab

I-Mab (IMAB) is restructuring its operating model for the US market, having completed a personnel overhaul and stabilized its R&D division. The company's capitalization relies on royalties and upfront payments from global pharma behemoths for the transfer of antibody rights. The stock's price chart with the indicator reflects the dynamics of an asset influenced by the BioSecure Act, geopolitics, and clinical trial outcomes.

This indicator determines the investment attractiveness of I-Mab (IMAB) through the weighted average of target prices from leading experts, reflecting market expectations for the asset's fair value. By analyzing the consensus target of analyst coverage, investors can assess the growth potential of the shares, which for I-Mab depends directly on the success of bispecific antibody development and the prospects of licensing deals with global pharmaceutical behemoths.